# ARL6IP5

## Overview
ARL6IP5 is a gene that encodes the protein ADP ribosylation factor like GTPase 6 interacting protein 5, also known as JWA or GTRAP3-18. This protein is involved in various cellular processes, including autophagy, bone metabolism, and neuroprotection. As a regulatory protein, ARL6IP5 plays a crucial role in stabilizing autophagy-related proteins, such as ATG12, and interacting with Rab1 to facilitate autophagosome formation, which is essential for cellular homeostasis and neuroprotection (Siddique2023ARL6IP5). In bone metabolism, ARL6IP5 is vital for osteoblast differentiation and maintaining endoplasmic reticulum calcium homeostasis, with its deficiency linked to bone loss and increased osteoclastogenesis (Wu2014Deficiency). Additionally, ARL6IP5 has been implicated in the modulation of DNA repair pathways in ovarian carcinoma, influencing chemotherapeutic resistance (Kim2022ARL6IP5). The gene's expression and function are of significant interest in the context of diseases such as Parkinson's disease and ovarian carcinoma, where it holds potential as a therapeutic target (Kim2022ARL6IP5; Siddique2023ARL6IP5).

## Function
ARL6IP5, also known as JWA, is a protein involved in several critical cellular processes. It plays a significant role in regulating autophagy, a cellular degradation process essential for maintaining cellular homeostasis. ARL6IP5 interacts with the autophagy-related protein ATG12, stabilizing it and preventing its ubiquitination and degradation. This stabilization promotes autophagy, which is crucial for degrading misfolded proteins and maintaining cellular health (Siddique2023ARL6IP5).

In the context of bone metabolism, ARL6IP5 is expressed in osteoblastic cells and is essential for osteoblast differentiation and proliferation. It maintains endoplasmic reticulum (ER) calcium homeostasis, which is vital for osteoblast function. ARL6IP5 deficiency leads to impaired osteoblast proliferation and differentiation, increased osteoclastogenesis, and bone loss due to disturbed calcium signaling and ER stress-mediated apoptosis (Wu2014Deficiency).

ARL6IP5 is also involved in neuroprotection, particularly in the context of neurodegenerative diseases like Parkinson's disease. It induces autophagy by enhancing Rab1-dependent autophagosome initiation and elongation, thereby reducing toxic protein aggregates such as α-synuclein (Siddique2023ARL6IP5).

## Clinical Significance
Alterations in the expression of the ARL6IP5 gene have been implicated in several diseases, including ovarian carcinoma, bone disorders, and neurodegenerative diseases like Parkinson's disease (PD). In ovarian carcinoma, ARL6IP5 is associated with reducing cisplatin resistance by promoting apoptosis and suppressing DNA repair pathways. Overexpression of ARL6IP5 in ovarian carcinoma cells enhances sensitivity to cisplatin, while its knockdown increases resistance, suggesting its potential as a therapeutic target to improve chemotherapeutic efficacy (Kim2022ARL6IP5).

In bone metabolism, ARL6IP5 deficiency leads to impaired osteoblast differentiation and increased osteoclastogenesis, resulting in decreased bone mineral density and bone loss. This is due to disturbances in endoplasmic reticulum calcium homeostasis and induction of ER stress-mediated apoptosis, highlighting its critical role in maintaining bone health (Wu2014Deficiency).

In neurodegenerative diseases, particularly Parkinson's disease, ARL6IP5 levels decrease with age and in disease models. Overexpression of ARL6IP5 reduces α-synuclein aggregates and enhances neuronal survival by promoting autophagy, indicating its potential as a therapeutic target for mitigating PD pathogenesis (Siddique2023ARL6IP5).

## Interactions
ARL6IP5, also known as JWA or GTRAP3-18, is involved in several protein interactions that play a crucial role in cellular processes. It interacts with the autophagy-related proteins ATG5 and ATG12, as demonstrated by co-immunoprecipitation experiments. This interaction is significant for the regulation of autophagy, as ARL6IP5 stabilizes ATG12 by preventing its ubiquitination and degradation, thereby enhancing autophagic processes (Siddique2023ARL6IP5). 

ARL6IP5 also interacts with Rab1, a protein involved in intracellular transport, which is crucial for autophagosome initiation and elongation. This interaction is part of the ARL6IP5/Rab1/ATG12 axis, which is important for neuroprotection in Parkinson's disease (Siddique2023ARL6IP5). 

In the context of ovarian carcinoma, ARL6IP5 interacts with XRCC1, a key component in DNA repair systems. This interaction influences the CK2-XRCC1 pathway, which is implicated in cisplatin resistance, highlighting ARL6IP5's role in modulating DNA repair and apoptosis (Kim2022ARL6IP5). 

Additionally, ARL6IP5 is activated by C/EBPα, which directly binds to the ARL6IP5 promoter, enhancing its expression and promoting apoptosis in certain cell lines (Wang2008Regulation).


## References


[1. (Kim2022ARL6IP5) Ji-Ye Kim, Entaz Bahar, Jung-Yun Lee, Sunhee Chang, Se Hoon Kim, Eun Young Park, Sung-Im Do, Hyonok Yoon, and Hyun-Soo Kim. Arl6ip5 reduces cisplatin-resistance by suppressing dna repair and promoting apoptosis pathways in ovarian carcinoma. Cell Death &amp; Disease, March 2022. URL: http://dx.doi.org/10.1038/s41419-022-04568-4, doi:10.1038/s41419-022-04568-4. This article has 7 citations.](https://doi.org/10.1038/s41419-022-04568-4)

[2. (Siddique2023ARL6IP5) Ibrar Siddique, Kajal Kamble, Sakshi Gupta, Kavita Solanki, Sumnil Bhola, Nuzhat Ahsan, and Sarika Gupta. Arl6ip5 ameliorates α-synuclein burden by inducing autophagy via preventing ubiquitination and degradation of atg12. International Journal of Molecular Sciences, 24(13):10499, June 2023. URL: http://dx.doi.org/10.3390/ijms241310499, doi:10.3390/ijms241310499. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241310499)

[3. (Wu2014Deficiency) Y Wu, M Yang, J Fan, Y Peng, L Deng, Y Ding, R Yang, J Zhou, D Miao, and Q Fu. Deficiency of osteoblastic arl6ip5 impaired osteoblast differentiation and enhanced osteoclastogenesis via disturbance of er calcium homeostasis and induction of er stress-mediated apoptosis. Cell Death &amp; Disease, 5(10):e1464–e1464, October 2014. URL: http://dx.doi.org/10.1038/cddis.2014.427, doi:10.1038/cddis.2014.427. This article has 27 citations.](https://doi.org/10.1038/cddis.2014.427)

[4. (Wang2008Regulation) Guo-Li Wang, Xiurong Shi, Elizabeth Salisbury, and Nikolai A. Timchenko. Regulation of apoptotic and growth inhibitory activities of c/ebpα in different cell lines. Experimental Cell Research, 314(7):1626–1639, April 2008. URL: http://dx.doi.org/10.1016/j.yexcr.2008.01.028, doi:10.1016/j.yexcr.2008.01.028. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2008.01.028)